ALLR - Allarity Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ALLR

ALLARITY THERAPEUTICS, INC.

NASDAQ

$1.41

▲ UP 2.17% (0.03)

KEY STATISTICS

Market Cap$22.43 M

52w High$2.06

52w Low$0.77

Dividend Yield—

Frequency—

P/E-1.86

Volume138.00K

Shares Out.15.91M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Thomas H. Jensen

COMPENSATION 2026

Salary$647,383

Stock Awards$400,701

Incentive Plan Pay$0

All Other Comp.$55,366

Total$1,458,950

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 21, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 13, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2024-09-11	Reverse	1:30
2024-04-09	Reverse	1:20
2023-06-29	Reverse	1:40
2023-03-27	Reverse	1:35

PRICE

$1.41 ▲ UP 2.17% (+$0.03)

OVERLAYS

About Allarity Therapeutics, Inc.

https://www.allarity.com ↗

Allarity Therapeutics, Inc. is a Cambridge-based clinical-stage biopharma developing oncology drugs like Stenoparib and Dovitinib, utilizing drug-specific diagnostics and advancing multiple candidates in Phase 2 trials.

INDUSTRY

Biotechnology

A PRODUCT ALLARITY THERAPEUTICS, INC. IS KNOWN FOR

Stenoparib (2X-121)

Stenoparib, an oral dual PARP and WNT inhibitor by Allarity Therapeutics, is in Phase 2 trials for ovarian and lung cancers, with FDA Fast Track designation for advanced ovarian cancer.